15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $5M | -$22M | 0.0% | -293.5% | -$21M | — | $4M |
| 2024 | $6M | -$13M | 0.0% | -252.3% | -$11M | — | $76000 |
| 2023 | $5M | -$13M | 0.0% | -271.1% | -$13M | — | $9M |
| 2022 | — | -$20M | — | — | — | $5M | $18M |
| 2021 | — | -$13M | — | — | — | $7M | $18M |
| 2020 | — | -$8M | — | — | — | — | $8M |
| 2019 | — | -$11M | — | — | -$6M | — | $18M |
| 2018 | — | -$13M | — | — | -$12M | — | $5M |
| 2017 | $3M | -$23M | 5.4% | -412.0% | -$18M | — | $10M |
| 2016 | $5M | -$22M | 41.7% | -423.2% | — | — | $13M |
| 2015 | $5M | -$19M | 34.1% | -316.0% | — | — | $14M |
| 2014 | $5M | -$37M | 40.6% | -654.9% | — | $25M | $15M |
| 2013 | $7M | -$26M | 52.0% | -430.8% | -$35M | $26M | $16M |
| 2012 | $9M | -$32M | 54.1% | -326.3% | -$33M | $23M | $26M |
| 2011 | $8M | -$32M | 51.9% | -368.4% | -$36M | — | $37M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $1M | -$7M | 0.0% | -692.5% | -$7M | — | $3M |
| Dec '25 | $1M | -$6M | 0.0% | -420.0% | -$6M | — | $4M |
| Sep '25 | $1M | -$4M | 0.0% | -320.8% | -$3M | — | $13M |
| Jun '25 | $1M | $5M | 0.0% | -110.6% | -$6M | — | $2M |
| Mar '25 | $1M | -$17M | 0.0% | -333.9% | -$6M | — | $10M |
| Dec '24 | $1M | -$4M | 0.0% | -276.2% | -$1M | — | $76000 |
| Sep '24 | $1M | -$3M | 0.0% | -260.9% | -$4M | — | $1M |
| Jun '24 | $1M | -$3M | 0.0% | -289.1% | -$1M | — | $5M |
| Mar '24 | $2M | -$3M | 0.0% | -196.7% | -$5M | — | $3M |
| Dec '23 | — | -$4M | — | — | -$2M | — | $9M |
| Sep '23 | — | -$3M | — | — | -$2M | — | $11M |
| Jun '23 | — | -$1M | — | — | -$3M | — | $11M |
| Mar '23 | — | -$5M | — | — | -$6M | — | $13M |
| Dec '22 | — | -$6M | — | — | — | $5M | $18M |
| Sep '22 | — | -$5M | — | — | -$4M | $6M | $20M |
| Jun '22 | — | -$5M | — | — | -$3M | $6M | $18M |
| Mar '22 | — | -$4M | — | — | -$4M | $6M | $21M |
| Dec '21 | — | -$4M | — | — | — | $7M | $18M |
| Sep '21 | — | -$4M | — | — | -$2M | — | $21M |
| Jun '21 | — | -$3M | — | — | -$2M | — | $17M |
How the market has priced PSTV against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, PLUS THERAPEUTICS, INC.'s revenue has grown 3.0% per year. These are computed facts, not advice.
As of FY2025, PLUS THERAPEUTICS, INC. reported — of total debt against $4M of cash; operating income covered interest expense -27.9×.
In FY2025, gross margin was —, operating margin -293.5%, and net margin -429.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.